Danish Biotech Pipeline is Number One in Europe  

2014.10.06

Danish biotech and drug companies are still among the best in Europe when it comes to the number of candidate drugs under development.

Danish biotech

According to the newly published ‘Nordic Life Sciences sector study 2014’ by Ernst & Young, Denmark has the largest pipeline of drugs undergoing clinical trials in Europe relative to its size. In 2013 Denmark had a total of 107 candidates in clinical phase I, II and III, surpassing even Sweden, who accounted for an impressive 93 clinical drug candidates.

A positive Danish drug development in spite of a general drop in funding
As previously outlined by the Danish medico newsletter MedWatch, the increase in Danish drug development looks even better in the light of the massive knocks the life science sector has taken during the fiscal crisis. In 2013, the capital raised by the biotech industry reached a low point of EUR 67 million.

Rasmus Beedholm-Ebsen, Ph.D. and Project Manager at Invest in Denmark, is not surprised about the strong Danish biotech pipeline:

“One of the reasons why Denmark’s pipeline of drug development is so strong is the high number of innovative biotech companies. Denmark has more than 160 biotech firms which is about equivalent to a country like France with a ten times larger population”, Rasmus Beedholm-Ebsen says and continues: “Even though many of the Danish biotech companies are relatively small, it is important to have a critical mass of research companies in the sector in order to get drugs into clinical development. Furthermore, it is crucial that the strong position in drug development is backed by a proven ability to take drug candidates into preclinical and clinical development and onto the market.”

Next step

Explore business cases

Contact

Rasmus Beedholm-Ebsen

Rasmus Beedholm-Ebsen

+45 2856 8540

rasbee@um.dk

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×